stoxline Quote Chart Rank Option Currency Glossary
  
Biomotion Sciences Ordinary Shares (SLXN)
1.35  -0.03 (-2.17%)    02-12 19:59
Open: 1.34
High: 1.4
Volume: 535,710
  
Pre. Close: 1.38
Low: 1.33
Market Cap: 5(M)
Technical analysis
2025-02-12 4:48:05 PM
Short term     
Mid term     
Targets 6-month :  2.74 1-year :  4.02
Resists First :  2.35 Second :  3.45
Pivot price 1.46
Supports First :  0.57 Second :  0.47
MAs MA(5) :  1.31 MA(20) :  1.29
MA(100) :  1.21 MA(250) :  6.35
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  27.2 D(3) :  26
RSI RSI(14): 47.3
52-week High :  13.55 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SLXN ] has closed above bottom band by 45.2%. Bollinger Bands are 49.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.4 - 1.41 1.41 - 1.41
Low: 1.31 - 1.32 1.32 - 1.33
Close: 1.34 - 1.35 1.35 - 1.36
Company Description

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Headline News

Fri, 29 Nov 2024
Silexion Therapeutics announces reverse share split, warrant adjustments - Investing.com

Thu, 15 Aug 2024
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination - StockTitan

Thu, 15 Aug 2024
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination - GlobeNewswire

Thu, 13 Feb 2025

Thu, 13 Feb 2025

Thu, 13 Feb 2025

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4 (M)
Shares Float 0 (M)
Held by Insiders 32.5 (%)
Held by Institutions 8.1 (%)
Shares Short 36 (K)
Shares Short P.Month 10 (K)
Stock Financials
EPS -13.23
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.67
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -62.2 %
Return on Equity (ttm) -116.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.34
Qtrly Earnings Growth 0 %
Operating Cash Flow -1 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.11
PEG Ratio 0
Price to Book value 0.28
Price to Sales 0
Price to Cash Flow -6.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android